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Abstract
The polyomavirus JC virus (JCV) is a small nonenveloped DNA virus that asymptomatically infects about 80% of 
healthy adults and establishes latency in the kidney tissue. In case of immunodeficient hosts, JCV can lytically infect 
the oligodendrocytes, causing a fatal demyelinating disease, known as Progressive Multifocal Leukoencephalopathy 
(PML). Although the reactivation of another human polyomavirus, BK Virus (BKV), is relatively common and its 
association with the Polyomavirus Associated Nephropathy (PVAN) following renal transplantation is assessed, JCV 
replication and its impact on graft function and survival is less well studied. In addition, none of the performed studies 
ruled out the hypothesis that JCV could be associated with certain post-transplantation clinical syndromes. Thus, 
monitoring of Polyomaviruses infection, especially during the first 24 months post-transplantation, is recommended.
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JC virus (JCV) is a member of the Polyomaviridae family, including 
naked DNA viruses with icosahedral capsids and small, circular, 
double-stranded DNA genomes. The natural hosts for polyomaviruses 
include humans, other primates, rodents, rabbits and birds [1]. 
Padgett et al. first isolated it in 1971 from the brain of a patient 
with the initial J.C., affected by Hodgkin’s Lymphoma who died of 
Progressive Multifocal Leukoencephalopathy (PML), a demyelinating 
disease of the Central Nervous System (CNS) [2]. PML is a rare 
disease characterized by the lytic infection of glial cells and is often 
fatal. The disease occurs almost exclusively in patients with severe 
immunodeficiency; consequently the incidence of PML has increased 
dramatically, following the spread of HIV/AIDS. Nowadays, HIV 
infection is still the most frequent setting for PML, ~80% of the 
cases, followed by hematologic malignancies (~8%), solid cancers 
(~3%), organ transplantation and autoimmune diseases treated with 
immunomodulators [3]. Indeed, successful treatments for PML are not 
currently available.
JCV does not infect any species other than humans and its ability 
to infect human cells may be restricted at the level of viral early gene 
transcription and DNA replication, with the protein named Large T 
Antigen (Tag) interacting specifically with the human DNA polymerase 
[4].
JCV has a tropism for replication in human glial cells, kidney 
epithelial cells and, with a less efficiency, in B lymphocytes, and the 
restricted CNS tropism is confirmed by both experimental animals and 
in vitro analysis [4,5]. 
The transmission of JCV is not fully understood. JCV-specific 
antibodies are detected in approximately 80% of adults and the primary 
infection occurs in early childhood, usually in an asymptomatic way 
and results in a primary viremia. Afterwards, the virus produces a 
persistent latent infection in the kidney and is shed into the urine. Since 
JCV may be detected in the tonsillar stromal cells, viral transmission 
via the respiratory route has been hypothesized, and the virus isolation 
in B lymphocytes suggested the lymphoid tissue as another site of viral 
latency with lymphocytes involved in viral circulatory dissemination 
to other anatomic sites [6,7]. The virus has also been detected in 
the gastrointestinal tract and in the raw urban sewage suggesting a 
possible oral or fecal transmission of JCV [8,9]. In the context of an 
immunosuppressive condition, such as AIDS and transplantation, 
JCV disseminates to the CNS and litically infects oligodendrocytes, 
causing the PML. Another hypothesis that explains the pathogenesis of 
PML states that: JCV may establish latency in normal brain tissue and 
reactivates in non immunocompetent hosts [10-12].
Reports of JCV infection in renal transplant recipients have been 
published immediately after the first isolation of the virus [13,14]. Since 
those times, subsequent works have investigated both the silent and the 
symptomatic infection and/or reactivation of JCV in the setting of kidney 
transplantation, finding contradictory results. Gardner and colleagues 
performed a wide prospective, serological study for the evidence of JCV 
infection in forty eight renal transplant recipients, finding that 54% of 
the patients were seropositive already before the operation, and that 
in 23% of the seronegative patients JCV infection occurred within the 
first three months after transplantation [15]. Molecular analysis were 
also conducted, by means of specific in situ Hybridization, PCR and 
Quantitative PCR assays by different international groups: JCV has 
been identified in kidney biopsy tissue and/or urine within a range 
of 3.4% and 46% of kidney transplanted patients, while JCV viremia 
ranged from 0% and 25% [16-24]. The most recent surveys, that had 
the possibility to measure the amount of replicating JCV in the clinical 
specimens, reported a very wide range of viral loads, from 2.0 ×103 
copies/ml to 1 × 107 copies/ml [17,19,21,22,24,25]. Only few studies 
analyzed also the molecular features of the isolated virus, observing 
that the JCV strains infecting the kidney transplantation recipients 
did not differ significantly from those infecting the immunocompetent 
subjects [21,25,26].
Regarding the non-kidney solid organ transplants (SOT), the 
incidence and clinical manifestation of JCV infection have been poorly 
investigated. In 2005, two independent groups published very different 
results about JCV infection in liver transplant patients, reporting 
1.7% and 22.7% of patients excreting the virus, respectively [24,27]. 
More recently, Kusne and colleagues observed that 71% of the studied 
patients excreted JCV after liver transplantation, with very high viral 
load (1.6 × 106 copies/ml) [28]. Studies on the association between JCV 
infection and lung, pancreas and heart transplantations are even rarer. 
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Although the different experimental approaches and the various 
results reported by the analyzed studies, they all agree that strict 
attention should be paid to monitoring JCV infection, especially during 
the first 24 months post-transplantation. In fact, even if JCV replication 
was mostly silent, it was not ruled out the hypothesis that it could be 
associated with certain clinical syndromes. 
In particular, infection by JCV has been observed in renal allograft 
recipients as both nephropathy and/or PML. PML occurs rarely in renal 
transplant patients and it is typically associated with high levels of viral 
genome found in the cerebrospinal fluid [29]. However, recent reports 
suggest that another polyomavirus, closely related to JCV, the BK Virus 
(BKV), can also cause a PML-like disease [30,31]. BKV was isolated in the 
VERO cell line from the urine of a renal transplant recipient and it was 
also named after the initials of the patient from whom it was isolated. In 
immunodepressed patient, BKV is responsible for severe diseases such 
as: upper respiratory tract infections, pneumonia, hemorrhagic cystitis, 
interstitial kidney disease, ureter stenosis, meningitis, encephalitis, 
retinitis, colitis and vasculitis. Furthermore, its reactivation may be 
associated with the onset of Polyomavirus Associated Nephropathy 
(PVAN), a serious complication of transplantation [32]. 
Renal transplant recipients have the highest risk of developing 
PVAN in comparison to other organ recipients because of the presence 
of ongoing graft injury due to drug toxicity, rejection episodes, cold 
ischemia and donor/recipients HLA mismatch [33-36]. PVAN 
with graft dysfunction and premature graft loss has been markedly 
increased since the 1990s [37,38], therefore a pathogenic potential of 
JCV should be taken into account. In contrast to the closely related 
BKV, to date, only few cases of nephropathy have been attributed to 
JCV [39-44]. Low level of JCV replication and shedding are common in 
immunocompetent individuals [45,46] but surprisingly the incidence 
of asymptomatic viruria is not increased in renal allograft recipients 
[47,48]. This suggests that immunosuppressive state is not as strictly 
related to development of PVAN as it is for BKV [49,50]. In addition, 
the immunosuppressive regimen does not play any important role and 
once JCV PVAN has established, the reduction of immunosuppression 
has a controversial impact on the clinical course [51]. However, a 
profound immunosuppressive state is required for a pathological and 
potentially threatening JCV replication. In fact, patients with PML have 
significant JCV viruria and PML and JCV PVAN have been reported 
to occur concurrently [43,52-54]. This arise the question whether 
anti-CD20 biological therapy with Rituximab in kidney transplant 
recipients is potentially cumbersome, because of a rapid depletion 
of pre-B and mature B-cells that lasts for at least six months upon 
its administration. Our recent report in a small cohort of pediatric 
kidney transplant recipients showed that rituximab treatment had no 
effect on susceptibility to JCV replication [25]. These findings confirm 
some reports on adult population treated with either rituximab [55] or 
different immunomodulator drugs such as natalizumab [56,57], where 
the risk of JCV new infection or reactivation was found inconsistent.
In a recent paper by Drachemberg and colleagues based on 
urine cytology and prospective protocol kidney biopsy in a cohort of 
hundred kidney transplant recipients, the incidence of JCV PVAN was 
reported as low as 0.9% despite the fact that a significant proportion 
of the patients displayed JCV viruria or decoy cell shedding [17]. 
Interestingly, the majority of JCV PVAN was diagnosed in patients 
with a normal renal function suggesting an apparently less aggressive 
or more protracted clinical course when compared with BKV PVAN. 
This was recently confirmed by Cheng et al. in a larger cohort of 
kidney transplant recipients where the clinical outcome of JCV viruric 
patients was reported to be favorable up to five years post transplant 
[58]. Compared to non-JCV viruric patients, rejection rate, graft 
survival and death-censored graft survival were lower and patient 
survival was similar. Based on their results, they also suggested that 
JCV reactivation occurs in the native kidney on immunosuppression 
rather than in the donor-derived graft in contrast to BKV [36]. Another 
important difference between BKV PVAN and JCV PVAN is the 
strong association with viremia and the severity of histological pattern 
in the former [59]. On the contrary, low level of JCV viremia has been 
reported either in patients shedding large amounts of JCV in urine or 
in patients with parenchymal involvement and this may be related to 
fundamental differences between BKV and JCV biology, which remain 
presently unexplained [16,27].
In conclusion, JCV PVAN is a unique clinical entity that needs 
to be differentiated from BKV PVAN. This requires viral typing 
methods that are not widely available and this should accounts for 
an underestimation of its incidence in kidney transplant recipients. 
However, the protracted and non-aggressive clinical course of the 
disease and the favorable outcome should be considered once this form 
of PVAN is diagnosed. Thus, monitoring of JCV infection, especially 
during the first 24 months post-transplantation, is recommended 
and the development of new, more sensitive technologies will be 
advantageous.
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